|
KMID : 1040620230290040958
|
|
Clinical and Molecular Hepatology
2023 Volume.29 No. 4 p.958 ~ p.968
|
|
|
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
|
|
Lee Sung-Uk
Kim Tae-Hyun
|
|
|
Abstract
|
|
|
|
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and external beam radiation therapy has emerged as a promising approach for managing HCC. Proton beam therapy (PBT) offers dosimetric advantages over X-ray therapy, with superior physical properties known as the Bragg peak. PBT holds promise for reducing hepatotoxicity and allowing safe dose-escalation to the tumor. It has been tried in various clinical conditions and has shown promising local tumor control and survival outcomes. A recent phase III trial demonstrated the non-inferiority of PBT in local tumor control compared to current standard radiofrequency ablation in early-stage HCC. PBT also tended to show more favorable outcomes compared to transarterial chemoembolization in the intermediate stage, and has proven effective in-field disease control and safe toxicity profiles in advanced HCC. In this review, we discuss the rationale, clinical studies, optimal indication, and future directions of PBT in HCC treatment.
|
|
|
KEYWORD
|
|
|
Carcinoma, hepatocellular, Radiotherapy, Proton therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|